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Abstract
Chorea-Acanthocytosis (ChAc) is a rare hereditary neurological disorder characterized by abnormal movements, red blood cell pathology, and progressive neuro-
degeneration. Little is understood of the pathogenesis of ChAc and related disorders (collectively Neuroacanthocytosis). The Eighth International Chorea-Acanthocytosis
Symposium was held in May 2016 in Ann Arbor, MI, USA, and focused on molecular mechanisms driving ChAc pathophysiology. Accompanying the meeting,
members of the neuroacanthocytosis research community and other invited scientists met in a workshop to discuss the current understanding and next steps needed
to better understand ChAc pathogenesis. These discussions identified several broad and critical needs for advancing ChAc research and patient care, and led to the
definition of 18 specific action points related to functional and molecular studies, animal models, and clinical research. These action points, described below,
represent tractable research goals to pursue for the next several years.
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Introduction
The Eighth International Chorea–Acanthocytosis Symposium was
held on May 14 and 15, 2016, in Ann Arbor, MI, USA. Previous
conferences were held in Seeon, Germany; Montreal, Que´bec, Canada;
London and Oxford, UK; Kyoto, Japan; Bethesda, MD, USA; Ede,
The Netherlands; and Stresa, Italy. Two comprehensive summary
volumes were among the outcomes of these meetings.1,2 The most
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recent neuroacanthocytosis symposium in Ann Arbor was accompa-
nied by an organized parallel patient meeting. It was attended by
16 families with patients affected by chorea–acanthocytosis (ChAc)
or McLeod syndrome, and was organized by the Advocacy for Neuro-
acanthocytosis Patients (www.naadvocacy.org).
The focus of the current scientific symposium was ChAc, functions
of the causative protein chorein (encoded by VPS13A; Table 1), and
related intracellular transport mechanisms (a full list of speakers
and topics is available at https://sites.google.com/a/umich.edu/chac
symposuim/home).
Accompanying the meeting, members of the neuroacanthocytosis
research community and other invited scientists met in a workshop
format to discuss current progress and critical next steps and experi-
ments needed to better understand ChAc pathogenesis. Topics
related to three broad themes were discussed: 1) the burgeon-
ing knowledge of yeast Vps13p function as a foundation for
understanding VPS13A biology and ChAc pathogenesis; 2) the status of
animal models of ChAc; 3) critical needs in ChAc clinical research and
patient care.
This document summarizes the workshop discussion and sets forth a
list of tractable action points for the ChAc research community. Readers
are directed to previous review articles and volumes for comprehensive
overviews of the field.1–3
Current understanding of VPS13 function: insights
from yeast models
Dr. Robert Fuller (University of Michigan) led a discussion outlining
current knowledge regarding the known functions of the Vps13 protein
(Vps13p) in yeast. Extensive work in yeast has provided a large number
of identifiable Vps13p cellular localizations, functions, and interactions
(Table 2, Figure 1). The yeast work is a rich source of hypotheses about
the functions of mammalian VPS13 homologues.4 Although there is
Table 1. VPS13 Nomenclature
Gene Protein
S. cerevisiae
VPS13 Vacuolar Protein Sorting-associated protein 13 (Vps13p)
D. melanogaster
Vps13 Vacuolar Protein Sorting-associated protein 13 (VPS13)
H. sapiens
VPS13A Chorein
Vacuolar Protein Sorting-associated protein 13A (VPS13A)
VPS13B Vacuolar Protein Sorting-associated protein 13B (VPS13B)
VPS13C Vacuolar Protein Sorting-associated protein 13C (VPS13C)
VPS13D Vacuolar Protein Sorting-associated protein 13D (VPS13D)
Table 2. Known Vps13p (yeast) Localizations, Functions, and Interactions
Localizations Functions Interactions
Late endosome/PVC TGN to PVC transport Cdc31p–yeast centrin
TGN TGN homotypic fusion
Nuclear–vacuolar junction Unknown
Prospore membrane
Prospore membrane maturation
and fusion
Spo71p
Vacuolar–mitochondrial junction Mitochondrial integrity Mcp1p
Lipid droplet aggregates Unknown
Abbreviations: PVC, Prevacuolar Compartment; TGN, Trans-Golgi network.
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significant understanding of Vps13p in yeast, the extent to which these
reflect the biological consequences of chorein function (and loss of function)
in mammalian cells and human tissue is unknown, and represents a
major gap in the field (Box 1).
Figure 1. Three-dimensional Architecture of Purified Yeast Vps13 Protein. The Vps13 structure was determined using negative-stain electron
micrograph image analysis. Further biochemical and structural analyses of yeast Vps13p are described in reference 19.
Box 1. Example of a critical experiment (Action point 1): characterize the rare human missense mutations that result in disease, but
do not cause loss of protein product
Discussions of yeast Vps13p studies led to the definition of multiple proposed experimental questions aimed at understanding the localizations, functions,
interactions, and cellular roles of VPS13A in human and other mammalian cells. The experimental goals relating to these characteristics are outlined as Action
points 1–10 above.
A recent estimate, based on more than 100 cases of already published and unpublished data, is that at least 95% of human VPS13A mutations lead to loss of
the protein product chorein when patient cell lysates are analyzed by Western blot.6–10 This demonstrates that VPS13A loss of function is a primary
pathogenic mechanism causing ChAc. The small number of patients with point mutations, but whose samples contain measureable chorein levels, present
with typical clinical symptoms and disease progression, suggesting that their mutations render chorein non-functional. Defining the effects of these missense
mutations will be a critical step toward understanding chorein structure–function relationships.
To achieve these goals, the fundamental effects of each known mutation must be established, including determining the level of RNA expression, protein
quantity, and whether alternative proteins are produced. The antibodies previously used recognize the N-terminal portion of the protein (approximately the
first 300 amino acids of the 3,174 amino acid chorein protein), but other available antibodies recognizing the C-terminal and internal sites are also available.
Antibodies to the C-terminal portion of chorein are likely the best option for diagnostic purposes.
Fundamental cell biological questions may be answered by introducing these point mutations into yeast (if the residue is conserved), Drosophila, or induced pluripotent
stem cells. These studies could be performed in parallel with lipidomic studies of VPS13A knockout cells and proteomics of wild-type cells. In this manner, the point
mutants could be used to understand fundamental biology and could provide a more comprehensive understanding of this complex protein.
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Yeast Vps13p is prominently localized to the late endosome/prevacuolar
compartment (LE/PVC), trans-Golgi network (TGN), peroxisome,
autophagosomes, and at membrane contact sites (Figure 2), including
mitochondrial–endosomal junctions, nuclear–vacuolar junctions, and
vacuole–mitochondrial junctions (vCLAMP, vacuole and mitochon-
dria patch).5 These widespread localizations position Vps13 to serve
potentially diverse cellular roles, including vesicular transport, TGN–
LE transport, TGN homotypic fusion, prospore membrane maturation,
and maintenance of mitochondrial integrity in pathways related to
the endoplasmic reticulum-mitochondria encounter structure (ERMES)
complex.
Although these roles are important, there are a number of addi-
tional interactions to consider. For example, recent data suggest that
Vps13p may stimulate the synthesis of several lipids, including PI(4)P
and PI(4,5)P2, and phosphatidic acid, which are rich in the prospore
membrane, and which also bind Vps13p. This suggests a possible
positive feedback loop in which Vps13p stimulates synthesis of lipids,
to which it also binds, leading to the promotion or organization of structures.
It is not fully understood how the protein stimulates this lipid synthesis,
but studies suggest potential recruitment of phospholipase D (Spo14p)
to the prospore membrane. As such, Vps13p may not solely create
junctions or catalyze lipid transfers, but could also initiate or potentiate
lipid synthesis. Investigating these functions may uncover potential
enzymatic targets amenable to drug therapy.
In the context of disease, a fundamental question is which Vps13p
functions are homologous in mammalian cells, particularly neurons,
and which functions are required for cell survival. In this context,
the yeast work is a solid foundation for hypothesis generation. The
association of yeast Vps13p with virtually all cellular organelles is a
unique property of the protein in comparison to other secretory
pathway (Sec)/vacuolar protein sorting (Vps) proteins. It is unclear
whether Vps13p performs the same common fundamental function in
each compartment and context, or distinct functions in different
subcellular contexts. It is currently unknown whether the mammalian
VPS13 homologues each have individual or multiple roles and local-
izations in mammalian cells, if there are tissue- or cell type-specific
differences in these characteristics, and if specific functions are impor-
tant for disease phenotypes. Therapeutic approaches targeting specific
compartments could be considered once these features are established.
An example of a yeast finding that generates hypotheses about
the functions of mammalian homologues, and that could lead to
a therapeutic target, is the role of Vps13p in TGN to PVC transport.
An in vitro system reconstituting TGN to PVC transport has been used
to infer VPS13p functions. In cell-free TGN to PVC transport, there is
a kinetic lag that implies the formation of an intermediate that
functions during a later step. In a typical vesicular transport reaction,
such a lag might correspond to transport vesicle formation. Unpublished
data presented at the workshop suggest that Vps13p and the phos-
phatidyl inositol/phosphatidyl choline transport protein, Sec14p, both
function during this lag. The role of Sec14p in stimulating synthesis of
PI(4)P at the Golgi suggests that the lag may represent the rebuilding of
PI(4)P pools on TGN membranes. Because there is evidence that
Vps13p stimulates PI(4)P synthesis on prospore membranes, it may
similarly stimulate PI(4)P synthesis in the TGN to PVC reaction.
A number of possible mechanisms could explain this putative role
(e.g., interaction with PIK1 or blockade of phosphatase function),
which begins to invoke potentially druggable enzymes. However, the
relevance of these pathways to human cells is unknown.
As another example, introduction of three different point mutations
found in ChAc patients into the yeast Vps13 results in separation-
of-function alleles. These mutations show specific defects in the
mitochondrial integrity aspect of Vps13 function. The common loss
of this specific activity in multiple alleles raises the possibility that the
human disease phenotypes are related to mitochondrial dysfunction.5
Further studies using this type of pathway-oriented approach in
yeast, red blood cells (RBCs), and other model systems (as described
below) may implicate additional potentially druggable targets. Beyond
in vitro studies, these putative pathways could be manipulated in cell
and animal models as a next step toward viable therapies.
Action points: VPS13 functional studies
1. Characterize the rare human missense mutations that result in
disease, but do not cause loss of protein product.
2. Characterize chorein localization in mammalian/human cells.
3. Define associated proteins/complexes.
4. Establish functional readouts/assays for mammalian cells.
5. Define the structure of human chorein isoforms.
6. Perform unbiased lipid profiling studies in mutant and control
cells.
7. Perform yeast synthetic tether experiments to model roles at
junctions.
8. Assess mitochondrial (and other organelle) function/dysfunction
in human cells.
9. Characterize autophagosome–lysosome fusion
10. Consider antisense transcript in knockout models
Figure 2. Yeast Vps13p Localization. Yeast Vps13 localization is
dependent on the carbon source. In cells grown in glucose (left ), Vps13–GFP is
present in cytoplasmic punctae that predominantly co-localize with endosomal
markers. When cells are grown in the non-fermentable carbon source acetate
(right ), Vps13–GFP concentrates at the membrane contact site between the
nuclear and vacuolar membranes. Dashed lines indicate the outlines of the
budding cells. Scale bar 5 5 mm. Further details regarding Vps13 localizations
have been previously published.5,18
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Animal models
Given the rarity of ChAc and related disorders and the relative
difficulty of clinical research, valid animal models are a high priority
for the field. Prior work has included mouse, tetrahymena,11 and dictyo-
stelium12 models. Drs. Ody Sibon (Groningen) and Andreas Hermann
(Dresden) led a discussion of the initial findings from newly developed
drosophila and mouse knockout models.
Dr. Sibon described a new Drosophila VPS13 knockout model that is
characterized by age-associated neurodegeneration, reduced locomo-
tor function in climbing assays, and premature death, which are
partially rescued with human VPS13A overexpression. This represents
the first ChAc model to exhibit overt neurodegeneration associated
with motor behavioral abnormalities.20 One notable feature of the
drosophila model is abrupt early mortality, which should be considered
further as a way to examine underlying pathophysiological mechanisms
and as a screening tool (Box 2). Further studies aiming to identify rescue
interventions of the fly model could provide a link toward human
therapies.
Dr. Hermann (Dresden) and Dr. Lucia De Franceschi (Verona)
discussed early work from VPS13A knockout mouse models (in addition
to a published, but not generally available prior mouse model),13,14 includ-
ing conditional knockout lines. Some similarities emerge through this work,
including infertility (particularly in male mice) and impaired autophagy.
To date, no overt neurological phenotypes have been observed in these
mouse lines, and neuropathological examinations have not been com-
pleted systematically.
Pathway-based approaches have been useful to generate hypotheses
in animal modeling research. For example, studies of RBCs from ChAc
patients provided first insights into possible functions of human chorein.
While RBC membrane lipid composition appears essentially normal,
patient erythrocytes demonstrate increased Lyn kinase activity.15
Unpublished data presented at the workshop demonstrated phenotypic
rescue in RBC and patient-derived neuronal cells with Lyn kinase
inhibition, suggesting Lyn kinase inhibition as a potential druggable
target.16 It is important to confirm if these abnormalities are present in
neurons and if they warrant future rescue studies with Lyn kinase inhi-
bitors. Compensation by other VPS family members, genetic background
effects, and age should be considered in the evaluation of mouse models.
Action points: ChAc animal model studies
11. Definitively characterize behavioral and neuropathological
phenotypes in new animal models.
12. Perform genetic and drug screening studies in Drosophila model.
13. Complete neuropathology and lipid profiling studies in VPS13
knockout mice.
Clinical research and patient care
The final discussion was led by Drs. Bernhard Landwehrmeyer
(Ulm) and Adrian Danek (Munich) and addressed our understanding
of the clinical features of ChAc.3 The ultimate goal of clinical research
in ChAc is to produce useful interventions and disease-modifying
therapies. A detailed understanding of phenotypic variation and natural
history is needed for planning good intervention studies (Box 3).
Because ChAc is a very rare disease, intervention studies will be handi-
capped by very small numbers of participants. Studies using clinical
endpoints must be based on well-characterized clinical instruments
and will probably require very large predicted intervention effect sizes.
Development of efficient biomarkers reflecting disease activity will be
crucial to circumvent these problems.
Another key objective of a clinical research network is the further
collection of patient and control biosamples for biomarker research.
Ideally, this would include a wide range of fluids (blood, serum,
cerebrospinal fluid), tissues, and post-mortem specimens. Facilitation
Box 3. Defining the natural history and progression of ChAc
The first clear clinical goal is to systematically define the natural history of ChAc. Common standards and rating scales need to be created and a significant
number of patients should be evaluated yearly. A wide range of clinical and imaging data should be collected. Additional presymptomatic identification
and phenotypic characterization of mutation carriers would assist in understanding the emergence and progression of ChAc features. As a model,
Dr. Landwehrmeyer discussed the ENROLL-HD study, a large observational natural history study for Huntington’s disease. There is already an effort to
collect phenotypic data in ChAc patients, which is structured as a submodule of the natural history registry in the European HD network (www.euro-hd.net/
html/na/submodule). While some data have been collected, several obstacles (notably its voluntary character and the rarity of ChAc) inhibit this effort.
International accumulation of data is required because of the rarity of ChAc, and is slowed by the need for multiple ethics boards approvals, preventing
individual clinicians and researchers from contributing data. An important goal would be to build on this network. Several logistical issues would need to be
considered, including how to make data widely available, how to use the network as a recruitment tool for future studies, and creating interfaces that will be
accessible to both participants and researchers in multiple languages.
Box 2. Example of critical experiment (Action point 12): genetic and drug screening studies in Drosophila model
The Drosophila VPS13 knockout model exhibits several unique features that position it as a powerful screening tool to examine genetic interactors, molecular
pathways, and novel drug targets. The sudden death phenotype is a distinct and easily quantifiable end point that provides a powerful advantage over other
model systems. One approach is to use ethyl methanesulfonate mutagenesis or interference RNA to screen for extragenic enhancers and suppressors.
If fundamental pathways are uncovered that protect from or accelerate premature death, further histopathological studies could be performed to determine
if manipulation of key pathway components prevents the formation of neuronal vacuoles. In conjunction with findings from yeast work, this may facilitate
identification of key pathways and therapeutic targets. This would lead to further studies in mammalian cells, mouse models, and human samples, and may
attract more researchers to the field.
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of biomarker studies should be a high priority. An accessible repo-
sitory, building upon a collection based at the neuropathology institute
of the University of Munich (blood and DNA samples, ChAc muscle
biopsies and brain tissue) will facilitate hypothesis-based, goal-directed
studies with appropriate materials. These materials are crucial for vali-
dation of pathogenesis and biomarker studies from animal models. Other
related disorders, including McLeod syndrome, diseases based on mutations
of VPS13C17 and VPS13D (poster at this symposium), and other HD-like
phenotypes could be included, particularly because these patients are being
cared for by many of the same physicians as ChAc patients.
It is possible that some of these activities could be done in parallel
with efforts in HD research, given the similar clinical context. Working
within the structures already in place for the study of HD will increase
geographical coverage, providing medical professionals who can assist
and perform quality monitoring, thereby creating more and higher
quality data for collaborative studies. Importantly, this along with the
longstanding support and extensive network activity by the Advocacy
for Neuroacanthocytosis Patients would also facilitate recruitment of
patients for imaging studies and for donation of biomaterials.
Bench researchers working on VPS13A biology or with animal
models should think actively about biological features in their studies
that could translate to markers of underlying pathologies and potential
biomarkers in patients. Plausible, well-defined functional readouts are
needed. Therapeutics should be based on the observed pathogenesis
and follow the identification of targets, rather than focusing on
untargeted broad high throughput approaches. Development of good
biomarkers is challenging and this will require many levels of col-
laboration between caregivers, clinical research, basic research, and
translational studies.
In parallel with this research network, another important project
would be to develop an internet platform for clinicians to easily discuss
experiences with management of ChAc patients. Because performing
multiple clinical trials is not feasible, sharing of clinical experience
and discussions among clinicians, patients, and caregivers offers the most
plausible route for near term improvement of the care of ChAc patients.
Action points: clinical care and research
14. Define natural history and progression of ChAc.
15. Develop standard rating instrument(s).
16. Develop a well-curated biorepository.
17. Conduct prospective, focused biomarker studies.
18. Further develop an internet-based resource and exchange for
physicians and medical professionals who assist patients.
Summary
The workshop discussions identified three broad critical needs for
advancing ChAc research:
i. Defining VPS13A functions that are critical to neuronal function
and survival.
ii. Definitive evaluation and exploitation of emerging animal and
cell models, including human cell models.
iii. Development of a comprehensive clinical research database,
including a well curated biorepository, particularly with a view to
defining suitable biomarkers.
ChAc research in the next several years should focus on these needs
and attempt to address the action points described above.
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